health · family: designed for a world that doesn’t exist here
sterilized andstill infectious
Reusable duodenoscopes cannot be reliably reprocessed between patients and are associated with drug-resistant infections
Problem statement
Reusable duodenoscopes cannot be reliably cleaned and disinfected between patients using current reprocessing methods. The instruments' interior channels and elevator recess hold tissue and fluid that are hard to remove, and FDA-ordered postmarket studies found organisms of high concern on 4 to 6% of samples from older fixed-endcap models after reprocessing. In the fall of 2013 the CDC alerted the FDA to a potential association between multi-drug-resistant bacteria and duodenoscopes, and the FDA found that infections, including ones caused by carbapenem-resistant Enterobacteriaceae (CRE), were occurring even where users were confirmed to be following the manufacturer's cleaning and disinfection or sterilization instructions. Human factors studies the FDA required of the manufacturers indicate that many steps in the reprocessing instructions cannot be reliably followed by health care facilities, and the FDA says that while it keeps working with manufacturers to revise their instructions, the best path to reducing the risk of disease transmission is innovative device design.
Why this matters
More than 500,000 ERCP (endoscopic retrograde cholangiopancreatography) procedures are performed annually in the United States, each requiring a duodenoscope. If the instrument is not thoroughly cleaned and disinfected, tissue or fluid from one patient can remain in it when it is used on the next, and the FDA says that in rare cases this can lead to patient-to-patient transmission of infection, including multi-drug-resistant bacteria. Between January 2013 and December 2014 alone, the FDA received 75 adverse event reports involving approximately 135 patients.
What’s been tried and why it hasn’t worked
The FDA first recommended in August 2019, and more firmly in April 2022, that healthcare facilities transition from fixed-endcap duodenoscopes to disposable-endcap or fully disposable designs. Pentax Medical received FDA clearance in 2024 for the first duodenoscope compatible with hydrogen peroxide gas plasma sterilization (STERRAD). However, fully disposable duodenoscopes cost significantly more per procedure than reprocessed reusable devices, creating economic barriers to adoption. Disposable designs may not yet match the mechanical performance — angulation precision and elevator control — of reusable instruments for complex ERCP cases. Most facilities worldwide continue to use reusable instruments. The core engineering difficulty is at the distal tip: the elevator recess must be cleaned of tissue and fluid, the moving parts of the elevator mechanism contain microscopic crevices that the FDA has said a brush may not reach, and on fixed-endcap models the permanently glued cap limits access to the crevices at the distal end. No test strip has been cleared by the FDA for checking duodenoscope cleaning: in 2019 the agency said it knew of no legally marketed ATP test strip cleared for this use and asked facilities not to rely on them.
What would unlock progress
A rapid, reliable point-of-use sterility verification test for endoscopes would immediately improve safety by catching reprocessing failures before the device is used on another patient. A redesigned elevator mechanism that eliminates internal recesses — maintaining ERCP functionality while enabling complete visual inspection and cleaning access — would address the root design deficiency. Significant cost reduction in disposable duodenoscope manufacturing could accelerate the transition away from reusable instruments by closing the per-procedure cost gap.
Entry points for student teams
A student team could develop a rapid biocontamination detection system for endoscope channels — for example, an ATP bioluminescence probe or fluorescence-based sensor designed to fit through the instrument's working channel and detect residual biological material in real time. Another entry point would be designing and prototyping an alternative elevator mechanism geometry that maintains the range of motion needed for ERCP while eliminating the internal recesses that trap contaminants. Teams with backgrounds in mechanical engineering, biomedical device design, microbiology, or optical sensing would be well-suited. A scoped semester project could focus on benchtop testing with surrogate contamination rather than clinical validation.
Genes
Structural cousins: stuck the same way, in other fields
Sources
FDA, "Infections Associated with Reprocessed Duodenoscopes," FDA CDRH, accessed 2026-02-19 go to source ↗
Working notes
Notes made while writing and checking this brief, shown as written. They use working shorthand.
Key references include the FDA page on infections associated with reprocessed duodenoscopes, FDA recommendation to transition to disposable components (news release of August 29, 2019, web.archive.org/web/20250506020628/www.fda.gov/news-events/press-announcements/fda-recommends-health-care-facilities-and-manufacturers-begin-transitioning-duodenoscopes-disposable), Gastroenterology journal analysis of single-use vs. reusable duodenoscopes (2024; Smith MW, Hernandez LV, Lee P, Martinello RA, Singh H, Sherman JD, "Single-Use vs Reusable Duodenoscopes: How Infection Knowledge Gaps Are Driving Environmental Harm and What Can Be Done," Gastroenterology 2024;167(3):426-431, doi 10.1053/j.gastro.2024.02.040), and MedTech Dive coverage of the FDA push for disposable duodenoscopes. The CDC alerted the FDA to a potential association between multi-drug resistant bacteria and duodenoscopes in the fall of 2013. Key industry players include Olympus, Fujifilm, Pentax Medical, Boston Scientific, and Ambu (disposable entrants). Tagged as "worsening" because ERCP procedure volumes are growing while the global installed base of reusable duodenoscopes remains very large and replacement timelines are measured in years. This brief illustrates the "design-for-reprocessability" gap — a pattern that may appear in other reusable medical instruments.
Reconciliation 2026-10-01: Fact repair after reading the whole write-up against the sources it names; a second reader went over the repairs the same day and adjusted the wording below. Read in full, all fetched 2026-10-01: the FDA page on the Source line (https://www.fda.gov/medical-devices/reprocessing-reusable-medical-devices/infections-associated-reprocessed-duodenoscopes, content current as of June 30, 2022); the FDA Safety Communication of February 19, 2015 that the FDA page describes and links in its timeline (Internet Archive copy, web.archive.org/web/20150301073941/www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm434871.htm); the FDA news release linked above (Internet Archive copy, dated August 29, 2019; the original address on fda.gov now returns a 404, so the archive link above is now written in the short form the link checker accepts); and two MedTech Dive articles found by search, since the notes above name "MedTech Dive coverage" without a link and either could be the one meant (https://www.medtechdive.com/news/fda-disposable-duodenoscope-reprocessing/621647/, April 6, 2022, and https://www.medtechdive.com/news/fda-urges-providers-manufacturers-to-transition-to-duodenoscopes-with-disp/562048/, August 30, 2019). The "Gastroenterology journal analysis of single-use vs. reusable duodenoscopes (2024)" was identified from the Crossref and PubMed records (its citation is now given above); only its opening paragraph and reference list are readable without a subscription, so its body was not read. (1) The long title said the infections carry "40-50% Mortality" and the body said CRE infections carry mortality rates of 40-50%. None of the sources read gives a mortality figure. The figure was removed from the title and the body. The title also said the scopes "cannot be reliably sterilized, causing" infections; the FDA speaks of reprocessing (cleaning and disinfection or sterilization) and of infections "associated with" reprocessed duodenoscopes. Old title: "Reusable Duodenoscopes Cannot Be Reliably Sterilized, Causing Drug-Resistant Infections with 40-50% Mortality". New title: "Reusable Duodenoscopes Cannot Be Reliably Reprocessed Between Patients and Are Associated with Drug-Resistant Infections". (2) "Approximately 500,000-700,000" ERCP procedures a year: the FDA page, the 2019 news release and the 2015 safety communication all say "more than 500,000"; the text now says that. (3) "Persistent contamination rates of 4-6% even when manufacturer instructions are followed exactly": the FDA page gives 4 to 6% as the rate of high-concern organisms found on older model duodenoscopes in the postmarket studies, and says separately that infections occurred despite confirmation that users were following the manufacturer's instructions. The sentence now says each of those things separately. (4) "This has caused MDRO outbreaks, particularly CRE, at hospitals across the United States" and "outbreaks have continued at hospitals worldwide" are not in the sources read; the 2015 safety communication speaks of publications and adverse event reports that "associate" such infections with reprocessed duodenoscopes. The text now gives what the FDA says: in the fall of 2013 the CDC alerted the FDA to a potential association between multi-drug resistant bacteria and duodenoscopes, and infections, including ones caused by carbapenem-resistant Enterobacteriaceae (CRE, the FDA's own term in the 2015 communication), occurred even where users were confirmed to be following the instructions. The line in the notes above that the CDC "first identified the association" was changed the same way. "Other complex endoscopes" was also removed from the first sentence; the sources are about duodenoscopes. (5) "A fundamental design deficiency rather than a compliance failure" is stronger than the news release, which says the human factors studies it required of the manufacturers indicate that many steps cannot be reliably followed, that the FDA continues to work with manufacturers to revise the instructions, and that the best path to reducing risk is innovative device design. The sentence now says that. (6) Sepsis, prolonged hospitalization and death, and "a single hospital-associated CRE outbreak can exceed $10 million," are not in the sources read and were removed; the paragraph now carries the FDA page's statement that in rare cases contamination can lead to patient-to-patient transmission of infection. (7) "The FDA recommended in 2022": the linked news release is dated August 29, 2019, and the FDA page and the 2022 MedTech Dive article show the recommendation was strengthened in April 2022. The body now gives both dates and the notes above give the news release its own date. (8) Recesses that "cannot be adequately cleaned or visually inspected" and "no point-of-use test exists": the news release names the elevator recess and says fixed endcaps limit access to clean the crevices at the distal end, and the 2015 safety communication says the moving parts of the elevator mechanism contain microscopic crevices that may not be reached with a brush; neither mentions visual inspection. On testing, the news release says the FDA knew of no legally marketed ATP test strip cleared for assessing duodenoscope cleaning and asked facilities not to rely on them. Both sentences now follow those sources. Readers taking up the ATP entry point should know of that FDA warning. Confirmed in the sources and left as written: the Source line title; "75 adverse event reports involving approximately 135 patients" between January 2013 and December 2014 (the 2015 safety communication: "75 MDRs encompassing approximately 135 patients in the United States"); duodenoscopes are used in ERCP; Olympus, Fujifilm, Pentax, Boston Scientific and Ambu as the makers (the last two with fully disposable scopes). NOT checked, and left as written: the 2024 Pentax clearance for hydrogen peroxide gas plasma sterilization; that disposable scopes cost significantly more per procedure and may not match reusable ones mechanically; that most facilities worldwide still use reusable scopes; and that ERCP volumes are growing. These may rest on the body of the Gastroenterology analysis, which could not be read; its readable opening names "costs" and "supply chain risks" among the downsides of single-use scopes, and the 2019 news release says an immediate transition is not possible for all facilities "due to cost and market availability." Genome tags untouched.